Table 2.
Baseline MRI measurements
| Variable | Total cohort | Dapagliflozin | Placebo | P-value |
|---|---|---|---|---|
| Participants randomized | 66 | 32 | 34 | |
| Absolute LV mass (g) | 123.96 ± 22.46 | 126.47 ± 20.54 | 121.61 ± 24.20 | 0.383 |
| LV mass index BSA (g/m2) | 59.95 ± 8.26 | 60.92 ± 7.76 | 59.04 ± 8.73 | 0.360 |
| EF (%) | 71.94 ± 5.86 | 71.31 ± 5.42 | 72.54 ± 6.27 | 0.398 |
| EDV (mLs) | 124.04 ± 24.07 | 127.63 ± 22.54 | 120.66 ± 25.29 | 0.243 |
| ESV (mLs) | 35.34 ± 10.63 | 37.17 ± 9.92 | 33.63 ± 11.13 | 0.178 |
| SV (mLs) | 88.42 ± 17.65 | 90.45 ± 16.36 | 87.03 ± 18.88 | 0.435 |
| Left atrial area | 23.91 ± 5.25 | 24.73 ± 5.86 | 23.13 ± 4.55 | 0.218 |
| VAT volume (cm3)a | 6372.55 ± 2038.19 | 6301.79 ± 1988.24 | 6437.06 ± 2110.43 | 0.792 |
| (n = 65) | (n = 31) | |||
| SCAT volume (cm3)a | 9135.8 ± 3425.26 | 9058.34 ± 3857.04 | 9213.27 ± 2994.46 | 0.860 |
| (n = 62) | (n = 31) | (n = 31) | ||
| VAT/SCAT volume ratioa | 0.77 ± 0.33 (n = 62) | 0.79 ± 0.31 (n = 31) | 0.74 ± 0.35 (n = 62) | 0.583 |
Data are mean ± SD, n (%).
EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LV, left ventricular; LVM, left ventricular mass; LVMI, left ventricular mass index; MRI, magnetic resonance imaging; SCAT, subcutaneous adipose tissue; SV, stroke volume; VAT, visceral adipose tissue.
a Some scans removed due to artefact making accurate VAT or SCAT measurement not possible – see text for details.